Company Description
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications.
The company’s product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis.
It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir.
The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
| Country | United States |
| Founded | 1995 |
| IPO Date | Mar 21, 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 120 |
| CEO | Jay Luly |
Contact Details
Address: 4 Kingsbury Avenue Watertown, Massachusetts 02472 United States | |
| Phone | 617 607 0800 |
| Website | enanta.com |
Stock Details
| Ticker Symbol | ENTA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0001177648 |
| CUSIP Number | 29251M106 |
| ISIN Number | US29251M1062 |
| Employer ID | 04-3205099 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jay R. Luly Ph.D. | President, Chief Executive Officer and Director |
| Dr. Yat Sun Or Ph.D. | Chief Scientific Officer |
| Dr. Scott T. Rottinghaus M.D. | Chief Medical Officer |
| Harry R. Trout III | Vice President of Finance and Interim Principal Financial Officer |
| Kathleen S. Capps CPA | Executive Director of Accounting, Controller and Interim Principal Accounting Officer |
| Jennifer Viera | Executive Director of Investor Relations and Corporate Communications |
| Matthew P. Kowalsky J.D. | Chief Legal Officer and Corporate Secretary |
| Nathaniel S. Gardiner J.D. | Consultant |
| Tara Lynn Kieffer Ph.D. | Chief Product Strategy Officer |
| Brendan Luu | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 20, 2026 | EFFECT | Notice of Effectiveness |
| Feb 13, 2026 | SCHEDULE 13G/A | Filing |
| Feb 11, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Feb 11, 2026 | 10-Q | Quarterly Report |
| Feb 9, 2026 | 8-K | Current Report |
| Feb 5, 2026 | SCHEDULE 13G/A | Filing |
| Jan 26, 2026 | ARS | Filing |
| Jan 26, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jan 26, 2026 | DEF 14A | Other definitive proxy statements |
| Jan 20, 2026 | SCHEDULE 13G/A | Filing |